From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
Arizona’s bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona’s universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
UArizona Aims to Provide Rapid Tests for First Responders, Those on Battlefields Exposed to Biothreats, Such as COVID-19
Thanks to a U.S. Department of Defense contract for as much as $9.5 million, the University of Arizona College of Medicine – Phoenix and partners aim to develop a portable device to easily and accurately detect biological threats, including the virus that causes COVID-19.
Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Executive Order on Increasing Drug Importation to Lower Prices for American Patients Executive Order on Access to Affordable Life-saving Medications The Fourth Executive Order, relating to “Most Favored Nations” pricing for Medicare Part B treatments is set to take effect on August […]
Innovators Get a Green Light from DOJ to Share Information That Could Expedite Future COVID-19 Treatments
Eli Lilly and Company, AbCellera Biologics, Amgen, AstraZeneca, Genentech, and GlaxoSmithKline recieved approval from DOJ on July 23, 2020 to share information about manufacturing facilities and other information that could enable them to expedite the production of monoclonal antibody treatments that are determined to be safe and effective to treat COVID-19.
Aesthetics Biomedical® Raises Multi-Million-Dollar Funding Round to Expand Vivace® and SoME® Skincare Products
Phoenix-based biomedical innovator holds numerous patents and trademarks in the rapidly growing aesthetics industry “Decathlon’s investment allows us to deliver these ground-breaking aesthetic treatments and products to providers and consumers and continue to build the most innovative solutions in the marketplace.”
- BIO5/BIOSA Faculty Industry Networking Event
- AZBioPEERS: Perfecting your “virtual” pitch
- A Glimpse Into the Mind of the Investor - Tips & Tricks to Raising Your Series A
- Arizona Bioscience Week - AZBW 2020
- 09/13/2020 - 09/19/2020
- AZBioPEERS: Investment activity in the age of COVID-19